Katsutaro Hirota, Averell H. Sherker, Masao Omata, Osamu Yokosuka, Kunio Okuda – 1 January 1987 – Adenine arabinoside is an antiviral agent which has been used in a number of clinical studies for the treatment of chronic infections with hepatitis B virus. In order to better understand its effects and mode of action, we treated ducks chronically infected with duck hepatitis B virus with a 2‐week course and monitored the effects of the drug on viral replication by studying duck hepatitis B virus DNA in liver and serum using molecular biological techniques.

Kim Krogsgaard, Bjarne ÖRskov Lindhardt, Jens Ole Nielsen, Poul Andersson, Peter Kryger, Jan Aldershvile, Jan Gerstoft, Court Pedersen – 1 January 1987 – The presence of antibodies to HTLV‐III and markers of active hepatitis B virus replication was examined in a longitudinal study of 33 consecutive male homosexual HBsAg carriers. The mean follow‐up time was 37 months (range = 4 to 109 months). All patients were initially hepatitis B virus DNA‐positive and HBeAg positive. Antibodies to HTLV‐III were detectable in eight patients while they were positive for both of these markers.

Kim Krogsgaard, Peter Kryger, Jan Aldershvile, Poul Andersson, Thorkild I. A. Sørensen, Jens Ole Nielsen, The Copenhagen Hepatitis Acuta Programme – 1 January 1987 – The presence of hepatitis B virus DNA and anti‐δ was examined in a longitudinal study of 24 patients known to be δ‐infected during the course from acute to chronic hepatitis B virus infection. Fifteen patients (63%) were hepatitis B virus DNA positive in the first serum sample. Eleven of 14 patients, who cleared hepatitis B virus DNA, did so following or at the same time as onset of δ‐infection.

Raymond J. Macdonald – 1 January 1987

Douglas R. Labrecque, Gregory Steele, Steven Fogerty, Michelle Wilson, James Barton – 1 January 1987 – Hepatic stimulator substance is a liver growth stimulator derived from the hepatocyte cytosol of weanling or regenerating adult rat livers. The present paper reports the almost 9,000‐fold purification of hepatic stimulator substance with an approximately 100,000‐fold increase in specific growth stimulator activity.

Pere Ginés, Enrique Quintero, Vicente Arroyo, Josep Terés, Miguel Bruguera, Antoni Rimola, Joan Caballería, Joan Rodés, Ciril Rozman – 1 January 1987 – To investigate the natural history of compensated cirrhosis, 293 consecutive patients without previous major complications (ascites, jaundice, encephalopathy or gastrointestinal hemorrhage) were studied in terms of morbidity (probability of developing decompensated cirrhosis during follow‐up) and survival. Patients were diagnosed by liver histology between 1968 and 1980. Median follow‐up was 63 months.

Günter Blobel – 1 January 1987

Hideo Ishii, Koji Saifuku, Toshihiko Namihisa – 1 January 1987 – Antimitochondrial antibodies are characteristically detected in sera of patients with primary biliary cirrhosis. The antigens to which the antimitochondrial antibodies in primary biliary cirrhosis sera react have been located in the mitochondrial inner membrane. We have reported on four mitochondrial inner membrane proteins, extracted from beef heart, which reacted with antimitochondrial antibodies of primary biliary cirrhosis. These four proteins had molecular weights of 70, 54, 51 and 45 kd.

B. A. Runyon – 1 January 1987 – An in situ isolated, perfused rat liver system was used to evaluate various opsonins for hepatic trapping and killing of encapsulated, virulent, type 3 pneumococci. Pneumococci were rapidly trapped in the liver in the presence of all potential opsonins including Hanks balanced salt solution with added colloid. However, with some of the potential opsonins the organisms remained viable and could be recovered from the liver. With others there was killing of pneumococci.

1 January 1987